Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

Stopped early

Conditions studied: Healthy

In brief

The purpose of this study is to obtain lymphocyte collections from normal healthy volunteer donors in order to create Good Manufacturing Practice grade banks of virus-specific and tumor-reactive T-cells of defined HLA type and restricting HLA allele readily available for therapeutic use.

Key facts

Study ID

NCT03114566

Run by

Memorial Sloan Kettering Cancer Center

People needed

1

Starts

2017-04-05

Expected to finish

2021-02-02

Last updated by the study team

2021-02-05

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Donors must satisfy standards including those set forth by FACT (Foundation for the Accreditation of Cellular Therapy) and the criteria specified in FDA 21 Code of Federal Regulations (CFR) 1271. Specifically, screening for risk factors for communicable disease as well as infectious disease screening by serologic and PCR testing as outlined below. Including testing for IV, Hepatitis B, Hepatitis C, HTLV I and II, CMV, EBV, and toxoplasmosis, westnile virus, syphilis, varicella zoster, and Chagas disease.
• Donors must be typed for HLA-A, B, C, DR and DQ at high resolution.
• Donors accrued at MSKCC must have a hemoglobin value > 10g/dl
• Donors must be capable of undergoing, at least, a single standard 2 blood volume leukapheresis or a donation of one unit of whole blood
• Donors must weight >/= 25 kg

You may not qualify if…

• HTLV/HIV (+) or Hepatitis B or C positive donors
• Donors who are pregnant

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.